Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest CHDI Foundation Inc. Stories

2012-08-14 02:29:46

CAMBRIDGE, Mass. and NEW YORK, Aug. 14, 2012 /PRNewswire/ -- GNS Healthcare, Inc. (GNS), the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with CHDI Foundation, Inc. (CHDI) to create a data-driven computer model of Huntington's disease (HD), a debilitating neurodegenerative disorder for which there are currently no effective therapies. Created using GNS's...

2012-07-26 10:27:33

PHILADELPHIA, July 26, 2012 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced a partnership with CHDI Foundation, Inc. to develop systems biology tools for Huntington's disease (HD) research. HD is a devastating neurodegenerative disorder that affects muscle coordination and leads to gradual cognitive decline and dementia; there are currently no effective...

2012-06-11 23:03:39

Models will facilitate a better understanding of the disease and aid in therapeutic development. Sioux Center, Iowa (PRWEB) June 11, 2012 CHDI Foundation, Inc. and Exemplar Genetics today announced a collaborative research agreement to create multiple miniature swine models of Huntington´s disease (HD), a devastating disorder for which there are currently no effective treatments. Models that mimic this debilitating disease are anticipated to accelerate both the understanding of the...

2011-09-06 07:00:00

CAMBRIDGE, Mass. and NEW YORK, Sept. 6, 2011 /PRNewswire/ -- Galenea Corp. and CHDI Foundation, Inc. have announced a collaboration to identify synaptic dysfunction linked to Huntington's disease (HD) utilizing Galenea's proprietary synaptic transmission drug discovery platform. Mounting evidence indicates that mutant huntingtin protein, the molecular defect in HD, disrupts normal synaptic function, contributing to the behavioral, cognitive, and motor symptoms of this devastating...

2011-08-11 07:00:00

CARLSBAD, Calif., Aug. 11, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and CHDI Foundation, Inc. announced today a renewal of their collaboration to discover and develop an antisense drug for the treatment of Huntington's disease (HD), a fatal neurodegenerative disorder. This collaboration builds upon earlier successful alliances in which CHDI, a non-profit biomedical research organization dedicated to the development of therapeutics for HD, provided funding to support...

2011-04-05 06:00:00

RICHMOND, Calif. and NEW YORK, April 5, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) and CHDI Foundation, Inc. have announced a collaboration to develop a novel therapeutic for Huntington's disease (HD) based on Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology. The ZFP therapeutic approach will target the huntingtin gene that causes HD, an inherited neurodegenerative disease for which there are currently no therapies available to slow disease...